CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES

• H. Quach,
• A. Nooka,
• O. Samoylova,
• C.P. Venner,
• T. Facon,
• A. Spencer,
• S.Z. Usmani,
• K. Weisel,
• M. Mateos,
• K. Kim,
• S. Grosicki,
• K. Suzuki,
• S. Delimpasi,
• M. Obreja,
• A. Zahlten-Kumeli

Affiliations

H. Quach

University of Melbourne, St. Vincent's Hospital, Melbourne, Australia

A. Nooka

Winship Cancer Institute, Emory University, Atlanta, United States

O. Samoylova

Nizhniy Novgorod Region Clinical Hospital, Nizhny Novgorod, Russia

C.P. Venner

Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada

T. Facon

Hôpital Claude Huriez, Lille, France

A. Spencer

Alfred Health-Monash University, Melbourne, Australia

S.Z. Usmani

Atrium Health, Charlotte, United States

K. Weisel

University Medical Center Hamburg-Eppendorf, Hamburg, Germany

M. Mateos

University Hospital Salamanca/IBSAL, Salamanca, Spain

K. Kim

Sungkyunkwan University, Samsung Medical Center, Seoul, Korea

S. Grosicki

Silesian Medical University, Katowice, Poland

K. Suzuki

Japanese Red Cross Medical Center, Tokyo, Japan

S. Delimpasi

General Hospital Evangelismos, Athens, Greece

M. Obreja

Amgen Inc., Thousand Oaks, United States

A. Zahlten-Kumeli

Amgen Inc., Thousand Oaks, United States